SCHEMBL308864

SCHEMBL308864

COc1c[c]cc2c1ncn2C1CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 1/20 0.36
CYP17A1 P05093 1/20 0.36
ADORA2A P29274 3/20 0.36
MAPK14 Q16539 1/20 0.34
GABRA2 P47869 2/20 0.33
CYP11B2 P19099 1/20 0.33
CHKA P35790 2/20 0.32
CHKB Q9Y259 1/20 0.32
PKM P14618 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
ADORA3 P0DMS8 2/20 0.31
ADORA1 P30542 2/20 0.31
PI4KA P42356 1/20 0.31
PI4K2B Q8TCG2 1/20 0.31
PI4K2A Q9BTU6 1/20 0.31
PI4KB Q9UBF8 1/20 0.31
ADORA2B P29275 1/20 0.31
PDE5A O76074 1/20 0.31
PDE1A P54750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL309229 0.72 ADORA2A (0.35) YTHDC1ADORA2AALDH1A1ADORA1PI4KA
SCHEMBL308897 0.71 PIP4K2A (0.36) PKMALDH1A1
SCHEMBL309161 0.70 ACACB (0.30)
SCHEMBL308730 0.69 PIP4K2A (0.31)
SCHEMBL308870 0.65 TOP2A (0.33)
SCHEMBL308430 0.62 ALDH1A1 (0.34) ALDH1A1PDE5APDE1APDE1BPDE1C
SCHEMBL23063522 0.61 HTT (0.52) CYP11B2PKMALDH1A1TP53
SCHEMBL308604 0.61 PTGDR2 (0.33) ALDH1A1
SCHEMBL16428243 0.60 NQO2 (0.37) CHKACHKBPKMALDH1A1TP53
SCHEMBL19820542 0.59 ADORA2A (0.51) YTHDC1ADORA2ACHKACHKBADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093389-B2 e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases MERCK SHARP & DOHME CORP. (US) 2012-01-10 US disclosed
US-20080171761-A1 Substituted spirochromanone derivatives MERCK SHARP & DOHME LLC 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171761-A1 Substituted spirochromanone derivatives CBR3, CBR1, CNKSR1 YTHDC1 2239/4885CYP17A1 1182/4885ADORA2A 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.